Cargando…
Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) have presented a major and common health concern worldwide due to their increasing prevalence and progressive development of severe pathological conditions such as cirrhosis and liver cancer. Alth...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367556/ https://www.ncbi.nlm.nih.gov/pubmed/37497008 http://dx.doi.org/10.7150/ijbs.85145 |
_version_ | 1785077405548806144 |
---|---|
author | Han, Dong Wook Xu, KangHe Jin, Zhe-Long Xu, Yong-Nan Li, Ying-Hua Wang, Lin Cao, Qilong Kim, Kee-Pyo Ryu, DongHee Hong, Kwonho Kim, Nam-Hyung |
author_facet | Han, Dong Wook Xu, KangHe Jin, Zhe-Long Xu, Yong-Nan Li, Ying-Hua Wang, Lin Cao, Qilong Kim, Kee-Pyo Ryu, DongHee Hong, Kwonho Kim, Nam-Hyung |
author_sort | Han, Dong Wook |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) have presented a major and common health concern worldwide due to their increasing prevalence and progressive development of severe pathological conditions such as cirrhosis and liver cancer. Although a large number of drug candidates for the treatment of NASH have entered clinical trial testing, all have not been released to market due to their limited efficacy, and there remains no approved treatment for NASH available to this day. Recently, organoid technology that produces 3D multicellular aggregates with a liver tissue-like cytoarchitecture and improved functionality has been suggested as a novel platform for modeling the human-specific complex pathophysiology of NAFLD and NASH. In this review, we describe the cellular crosstalk between each cellular compartment in the liver during the pathogenesis of NAFLD and NASH. We also summarize the current state of liver organoid technology, describing the cellular diversity that could be recapitulated in liver organoids and proposing a future direction for liver organoid technology as an in vitro platform for disease modeling and drug discovery for NAFLD and NASH. |
format | Online Article Text |
id | pubmed-10367556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-103675562023-07-26 Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases Han, Dong Wook Xu, KangHe Jin, Zhe-Long Xu, Yong-Nan Li, Ying-Hua Wang, Lin Cao, Qilong Kim, Kee-Pyo Ryu, DongHee Hong, Kwonho Kim, Nam-Hyung Int J Biol Sci Review Non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH) have presented a major and common health concern worldwide due to their increasing prevalence and progressive development of severe pathological conditions such as cirrhosis and liver cancer. Although a large number of drug candidates for the treatment of NASH have entered clinical trial testing, all have not been released to market due to their limited efficacy, and there remains no approved treatment for NASH available to this day. Recently, organoid technology that produces 3D multicellular aggregates with a liver tissue-like cytoarchitecture and improved functionality has been suggested as a novel platform for modeling the human-specific complex pathophysiology of NAFLD and NASH. In this review, we describe the cellular crosstalk between each cellular compartment in the liver during the pathogenesis of NAFLD and NASH. We also summarize the current state of liver organoid technology, describing the cellular diversity that could be recapitulated in liver organoids and proposing a future direction for liver organoid technology as an in vitro platform for disease modeling and drug discovery for NAFLD and NASH. Ivyspring International Publisher 2023-07-09 /pmc/articles/PMC10367556/ /pubmed/37497008 http://dx.doi.org/10.7150/ijbs.85145 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Han, Dong Wook Xu, KangHe Jin, Zhe-Long Xu, Yong-Nan Li, Ying-Hua Wang, Lin Cao, Qilong Kim, Kee-Pyo Ryu, DongHee Hong, Kwonho Kim, Nam-Hyung Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title | Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title_full | Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title_fullStr | Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title_full_unstemmed | Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title_short | Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
title_sort | customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367556/ https://www.ncbi.nlm.nih.gov/pubmed/37497008 http://dx.doi.org/10.7150/ijbs.85145 |
work_keys_str_mv | AT handongwook customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT xukanghe customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT jinzhelong customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT xuyongnan customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT liyinghua customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT wanglin customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT caoqilong customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT kimkeepyo customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT ryudonghee customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT hongkwonho customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases AT kimnamhyung customizedliverorganoidsasanadvancedinvitromodelinganddrugdiscoveryplatformfornonalcoholicfattyliverdiseases |